$SEM (Select Medical Holdings Corporation)

$SEM {{ '2016-06-01T20:12:47+0000' | timeago}} • Announcement

$SEM said it has partially completed its previously announced transaction to exchange long term acute care hospitals with $KND. $SEM has transferred hospitals in Indianapolis, IN, Houston, TX, Denver, CO and Colorado Springs, CO to $KND. $KND has transferred two hospitals in Cleveland, OH to $SEM.

$ABBV {{ '2017-07-28T12:13:15+0000' | timeago}} • Announcement

Global HUMIRA sales for $ABBV rose 13.7% in 2Q17, while Global IMBRUVICA net revenues jumped 42.6%. The gross margin ratio in the second quarter was 78.0%, with adjusted gross margin ratio at 82.3%.

$ABBV {{ '2017-07-28T12:04:31+0000' | timeago}} • Announcement

While posting 2Q17 results, $ABBV confirmed its GAAP diluted EPS guidance for FY17 of $4.55-4.65. AbbVie expects to deliver adjusted diluted EPS of $5.44 to $5.54, representing growth of 13.% at the mid-point.

$ABBV {{ '2017-07-28T12:02:43+0000' | timeago}} • Announcement

With the biopharma giant's net revenues up 7.6% to $6.9Bil in 2Q17, $ABBV's net earnings soared 19% to $1.9Bil or $1.19 per share.  Adjusted diluted EPS was $1.42, up 12.7% in the quarter.

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$BMY {{ '2017-07-25T15:05:20+0000' | timeago}} • Announcement

The FDA has accepted $BMY's supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The applications are under review with an action date of March 5, 2018. Opdivo has become important treatment option across multiple cancers.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$CYH {{ '2017-07-24T10:52:14+0000' | timeago}} • Announcement

$CYH's subsidiaries agreed to sell 126-bed Highlands Regional Medical Center in Sebring, Florida, and its associated assets to subsidiaries of $HCA. The transaction is expected to close in the fall of 2017.

$HCA {{ '2017-07-21T20:39:36+0000' | timeago}} • Announcement

$HCA has agreed to acquire Highlands Regional Medical Center in Sebring, Florida, from subsidiaries of Community Health Systems, Inc. The transaction, which is subject to regulatory approvals and other closing conditions, is expected to close in the fall of 2017.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$HLS {{ '2017-07-20T13:56:35+0000' | timeago}} • Announcement

The BoD of $HLS declared a quarterly cash dividend on its common stock of $0.25 per share. The dividend is payable on Oct. 16, 2017, to stockholders of record on Oct. 2, 2017.

$UHS {{ '2017-07-19T22:35:19+0000' | timeago}} • Announcement

$UHS BoD approved a cash dividend of $0.10 per share on Sept. 15, 2017 to shareholders of record as of Sept. 1, 2017.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$DVA {{ '2017-07-13T12:17:02+0000' | timeago}} • Announcement

DaVita Medical Group, a division of $DVA, acquired Dr. Rahn Shaw's practices, Park Avenue Medical Inc. and Winter Park Health Center Inc., each located in Orlando. Dr. Shaw has been an affiliate with DaVita Medical Group since 2005. Under the terms, the practices will be branded "DaVita Medical Group".

$QHC {{ '2017-07-12T19:46:10+0000' | timeago}} • Announcement

$QHC's affiliate signed a letter of intent to sell 72-bed L.V. Stabler Memorial Hospital in Greenville, Alabama and its associated assets, to the City of Greenville, Alabama. The divestiture is expected to close by Sept. 30, 2017.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
UHS (Universal Health Services Inc.)
Wednesday, July 26 2017 - 1:00pm
HCA (HCA Holdings, Inc.)
Tuesday, July 25 2017 - 2:00pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
QHC (Quorum Health Corporation)
Monday, May 15 2017 - 3:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
GEN (Genesis Healthcare, Inc.)
Tuesday, May 9 2017 - 2:00pm
BKD (Brookdale Senior Living Inc.)
Tuesday, May 9 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
FVE (Five Star Quality Care Inc.)
Friday, May 5 2017 - 2:00pm
SEM (Select Medical Holdings Corporation)
Friday, May 5 2017 - 1:00pm
MD (MEDNAX, Inc.)
Thursday, May 4 2017 - 2:00pm
KND (Kindred Healthcare Inc.)
Thursday, May 4 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Wednesday, May 3 2017 - 1:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, May 2 2017 - 9:00pm
HCA (HCA Holdings, Inc.)
Tuesday, May 2 2017 - 3:00pm
THC (Tenet Healthcare Corp.)
Tuesday, May 2 2017 - 2:00pm

AlphaGraphics you may like